Navigation Links
Advanced Prenatal Therapeutics Appoints Dr. Nihar Nayak to its Scientific Advisory Board
Date:7/29/2013

LAGUNA HILLS, Calif., July 29, 2013 /PRNewswire/ -- Advanced Prenatal Therapeutics, Inc. (APT), a private company developing the first medical device specifically designed to treat preeclampsia, is happy to announce the appointment of its first scientific advisor: Nihar Nayak, PhD, DVM. Dr. Nayak brings to the table over 16 years of research experience and a passion for the development of novel products to treat preeclampsia.

Dr. Nayak is an Associate Professor of Obstetrics and Gynecology (Research) and the Director of Translational Research in the Division of Maternal Fetal Medicine at Stanford University School of Medicine. As a key scientific leader in the prenatal field with extensive expertise in translational research, Dr. Nayak will offer APT a valuable perspective on product development and study design.

"His prior work with sFlt-1 and his expertise in translational research make him exceptionally valuable as an advisor and research collaborator," explains Dr. James Smith, CEO and President of APT. "Dr. Nayak's affiliation with Stanford's world-class research and clinical environment provides us with extraordinary resources and opportunities to advance our product commercialization efforts."

One of Dr. Nayak's major research goals is to understand the uterine mechanisms that affect blood vessel development during preeclampsia and to facilitate the translation of cutting edge research into new therapies. "Preeclampsia, a leading cause of prematurity and maternal and fetal death, is a completely unmet medical need," explains Dr. Nayak. "Research and development using therapeutic targets like sFlt-1 and other circulating factors could open the door to much needed therapies for preeclampsia patients."

Dr. Nayak has received several research awards, including the Lalor Foundation postdoctoral fellowship, the Andrew Mellon Foundation Junior Investigator Award, and the NIH BIRCWH award. Recently, Dr. Nayak also received a Vision Grant from the Preeclampsia Foundation to study the role of placental proteins in preeclampsia with a focus on sFlt-1 and vascular endothelial growth factor VEGF, the biomarkers affected by APT's initial product development efforts.

About Advanced Prenatal Therapeutics, Inc. (www.advancedprenatal.com) Advanced Prenatal Therapeutics, Inc.'s mission is to develop treatments for preeclampsia that will safely prolong pregnancy. To accomplish this goal, APT is developing a novel therapeutic device for preeclampsia that specifically removes disease-causing factors from the mother's blood. This press release may contain forward-looking statements. There can be no assurance that development efforts will succeed, or that the novel therapeutic products will receive regulatory clearance, or achieve commercial success.

Investor Relations:
Dan Thiel
Advanced Prenatal Therapeutics, Inc.
949.340.7261
dthiel@advancedprenatal.com


'/>"/>
SOURCE Advanced Prenatal Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis
2. Advanced Circulatory Selects Combat Medical Systems As Its Exclusive Sales Distributor for Military and Federal Market in US
3. WebPAX v8 - The fastest, most technologically advanced zero-footprint medical image viewer yet
4. New RCSA Certification Curriculum Uses Angio Mentor Simulators for Advanced Training
5. JDRF Announces Two Partnerships to Develop Stable, Pumpable Glucagon to Support Advanced Generation Artificial Pancreas Systems
6. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
7. Belrose Pharma Acquires Enzons Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies
8. New drug proving effective in attacking advanced prostate cancer
9. Ochsner Health System Improves Safety Through Advanced Medication Management Technology
10. Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
11. New Air Products Microsite Features Advanced Liquid Nitrogen Solutions for the Chemical, Pharmaceutical, and Life Science Industries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... Aug. 7, 2017 Insightin Health, provider ... retention, and engagement, announced the selection of ... Product Development, effective as of February 2017. In this ... implementation strategy for our clients. Wood brings with ... consulting and business analytics within the healthcare industry. ...
(Date:8/7/2017)... Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the ... quarter ended June 30, 2017.  All comparisons, unless otherwise noted, ... Second Quarter 2017 Highlights include: ... $1,089 million, an increase of 3.5% Total ... Gross margin of 7.5% versus 7.6% ...
(Date:8/4/2017)...  Agragen, LLC, a Cincinnati ... nutraceutical, and aquacultural feed sectors, announces a significant ... candidates, AGR131.  This drug is designed to trap ... of patients suffering from inflammatory conditions such as ... Biological pharmaceuticals currently ...
Breaking Medicine Technology:
(Date:8/17/2017)... MA (PRWEB) , ... August 17, 2017 , ... ... home care professionals, today announced that it has raised $1.675 M in seed ... , Rethink Education, Lumina Foundation, and Techstars Venture Capital Fund are the company’s ...
(Date:8/17/2017)... ... 2017 , ... Advice Media, the industry leader in digital marketing for medical practices, has been ... been included in the Inc. 5000 for the second time in two years. Shawn Miele, ... Inc. 5000 rankings for the second year in a row. It’s extremely difficult to make ...
(Date:8/17/2017)... ... August 17, 2017 , ... Navigating ... a Florida-based oncology business advisor to oncology practices, announced today the results of ... of attributable savings from resolving critical clinical issues that would have otherwise resulted ...
(Date:8/16/2017)... , ... August 16, 2017 , ... An August 3rd article on Reuters ... subject of a report in JAMA (the Journal of the American Medical Association). The study ... able to achieve BMIs under 30, when compared to patients with lower BMIs. At present, ...
(Date:8/16/2017)... GA (PRWEB) , ... August 16, 2017 , ... ... new Inc. 5000. The company ranked #4429 on the newly released, 36th annual ... list represents a unique look at the most successful companies within the American economy’s ...
Breaking Medicine News(10 mins):